163 related articles for article (PubMed ID: 20883676)
21. Clinical significance of simultaneous determinations of alpha-fetoprotein and des-gamma-carboxy prothrombin in monitoring recurrence in patients with hepatocellular carcinoma.
Aoyagi Y; Oguro M; Yanagi M; Mita Y; Suda T; Suzuki Y; Hata K; Ichii K; Asakura H
Cancer; 1996 May; 77(9):1781-6. PubMed ID: 8646674
[TBL] [Abstract][Full Text] [Related]
22. [Clinical signification and evaluation of PIVKA-II in hepatocellular carcinoma].
Matsushima A; Enomoto M; Yokoo Y; Arai M; Kobayashi T; Okuno F; Hirano Y; Sujita K; Eto S; Takagi T
Rinsho Byori; 1989 Jun; 37(6):683-6. PubMed ID: 2477568
[No Abstract] [Full Text] [Related]
23. Serum levels of des-gamma-carboxy prothrombin measured using the revised enzyme immunoassay kit with increased sensitivity in relation to clinicopathologic features of solitary hepatocellular carcinoma.
Okuda H; Nakanishi T; Takatsu K; Saito A; Hayashi N; Takasaki K; Takenami K; Yamamoto M; Nakano M
Cancer; 2000 Feb; 88(3):544-9. PubMed ID: 10649245
[TBL] [Abstract][Full Text] [Related]
24. Serum des-gamma-carboxyprothrombin level by a modified enzyme immunoassay method in hepatocellular carcinoma: clinical significance in small hepatocellular carcinoma.
Soga K; Watanabe T; Aikawa K; Toshima M; Shibasaki K; Aoyagi Y
Hepatogastroenterology; 1998; 45(23):1737-41. PubMed ID: 9840138
[TBL] [Abstract][Full Text] [Related]
25. Prognostic values of alpha-fetoprotein and protein induced by vitamin K absence or antagonist-II in hepatitis B virus-related hepatocellular carcinoma: a prospective study.
Kim HS; Park JW; Jang JS; Kim HJ; Shin WG; Kim KH; Lee JH; Kim HY; Jang MK
J Clin Gastroenterol; 2009; 43(5):482-8. PubMed ID: 19197197
[TBL] [Abstract][Full Text] [Related]
26. The des-gamma-carboxyprothrombin for the diagnosis of hepatocellular carcinoma.
Brunello F; Marcarino C; Pasquero P; Gastaldi P; Gonella S; Martini S; Calcamuggi G; Emanuelli G
Ital J Gastroenterol; 1993 Jan; 25(1):9-12. PubMed ID: 7679014
[TBL] [Abstract][Full Text] [Related]
27. [Early diagnosis of hepatocellular carcinoma by serum AFP and PIVKA-II analysis].
Aoyagi Y; Yanagi M; Asakura H
Nihon Naika Gakkai Zasshi; 1995 Dec; 84(12):2003-7. PubMed ID: 8586921
[No Abstract] [Full Text] [Related]
28. Abnormal prothrombin (PIVKA-II) and hepatocellular carcinoma.
Okuda H; Nakanish T; Furukawa M; Yamagata H; Obata H
Trop Gastroenterol; 1991; 12(2):59-66. PubMed ID: 1719681
[No Abstract] [Full Text] [Related]
29. Differential tumor markers and hepatitis markers profile in liver tumors.
Khalifa A; Mady EA; Abadeer N; Kamal A
Anticancer Res; 1999; 19(4A):2495-500. PubMed ID: 10470181
[TBL] [Abstract][Full Text] [Related]
30. Use of serum PIVKA-II (DCP) determination for differentiation between benign and malignant liver diseases.
Lamerz R; Runge M; Stieber P; Meissner E
Anticancer Res; 1999; 19(4A):2489-93. PubMed ID: 10470180
[TBL] [Abstract][Full Text] [Related]
31. Early detection of hepatocellular carcinoma associated with cirrhosis by combined assay of des-gamma-carboxy prothrombin and alpha-fetoprotein: a prospective study.
Izuno K; Fujiyama S; Yamasaki K; Sato M; Sato T
Hepatogastroenterology; 1995; 42(4):387-93. PubMed ID: 8586374
[TBL] [Abstract][Full Text] [Related]
32. [The clinical significance of PIVKA-II in hepatocellular carcinoma: a comparative study with alpha-fetoprotein: preliminary report].
Sakon M; Monden M; Gotoh M; Kanai T; Umeshita K; Endoh W; Mori T
Nihon Geka Gakkai Zasshi; 1989 Jul; 90(7):1129. PubMed ID: 2477681
[No Abstract] [Full Text] [Related]
33. [Optimal cut-off value of PIVKA-II for diagnosis of hepatocellular carcinoma--using ROC curve].
Kim MJ; Bae KW; Seo PJ; Jeong IK; Kim JH; Lee BH; Bang KT; Kim DW; Song IH
Korean J Hepatol; 2006 Sep; 12(3):404-11. PubMed ID: 16998292
[TBL] [Abstract][Full Text] [Related]
34. Des-gamma-carboxy prothrombin (DCP) ratio is a useful prognostic tumor marker for single nodule hepatocellular carcinoma (HCC).
Murakami N; Tamano M; Yoneda M; Sugaya H; Hiraishi H
Hepatogastroenterology; 2008; 55(81):197-201. PubMed ID: 18507106
[TBL] [Abstract][Full Text] [Related]
35. [PIVKA-II as a serological marker of hepatocellular carcinoma].
Jeong SH
Korean J Hepatol; 2006 Sep; 12(3):315-7. PubMed ID: 16998285
[No Abstract] [Full Text] [Related]
36. Prediction of recurrence of hepatocellular carcinoma after curative ablation using three tumor markers.
Tateishi R; Shiina S; Yoshida H; Teratani T; Obi S; Yamashiki N; Yoshida H; Akamatsu M; Kawabe T; Omata M
Hepatology; 2006 Dec; 44(6):1518-27. PubMed ID: 17133456
[TBL] [Abstract][Full Text] [Related]
37. Sensitive measurement of serum abnormal prothrombin (PIVKA-II) as a marker of hepatocellular carcinoma.
Tanaka Y; Kashiwagi T; Tsutsumi H; Nagasawa M; Toyama T; Ozaki S; Naito M; Ishibashi K; Azuma M
Hepatogastroenterology; 1999; 46(28):2464-8. PubMed ID: 10522021
[TBL] [Abstract][Full Text] [Related]
38. Sequential fluctuation pattern of serum des-gamma-carboxy prothrombin levels detected by high-sensitive electrochemiluminescence system as an early predictive marker for hepatocellular carcinoma in patients with cirrhosis.
Shimizu A; Shiraki K; Ito T; Sugimoto K; Sakai T; Ohmori S; Murata K; Takase K; Tameda Y; Nakano T
Int J Mol Med; 2002 Mar; 9(3):245-50. PubMed ID: 11836630
[TBL] [Abstract][Full Text] [Related]
39. Surveillance program for early detection of hepatocellular carcinoma in Japan: results of specialized department of liver disease.
Ando E; Kuromatsu R; Tanaka M; Takada A; Fukushima N; Sumie S; Nagaoka S; Akiyoshi J; Inoue K; Torimura T; Kumashiro R; Ueno T; Sata M
J Clin Gastroenterol; 2006; 40(10):942-8. PubMed ID: 17063116
[TBL] [Abstract][Full Text] [Related]
40. [Decarboxyprothrombin: importance in the diagnosis of hepatocellular carcinoma].
Bon C; Brillard B; Gelineau MC; Mailliavin A; Trépo C; Pichot J
Ann Biol Clin (Paris); 1998; 56(2):175-81. PubMed ID: 9754243
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
